Analysts’ expectations for Corcept Therapeutics Incorporated (CORT) stock: $30.67 price target in 12 months

Corcept Therapeutics Incorporated [CORT] stock prices are down -0.69% to $24.52 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CORT shares have gain 1.95% over the last week, with a monthly amount glided 10.30%, and seem to be holding up well over a long-time horizon.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


On 3, May 2023, Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update. In a post published today on Yahoo Finance, Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2023.

From an analyst’s perspective:

The stock price of Corcept Therapeutics Incorporated [CORT] has been fluctuating between $17.86 and $30.14 over the past year. Currently, Wall Street analysts expect the stock to reach $30.67 within the next 12 months. Corcept Therapeutics Incorporated [NASDAQ: CORT] shares were valued at $24.52 at the most recent close of the market. An investor can expect a potential return of 25.08% based on the average CORT price forecast.

Analyzing the CORT fundamentals

The most recent quarter, Corcept Therapeutics Incorporated [NASDAQ:CORT] reported sales of 105.65 billion, representing a surge of 12.80%. In the same period, the company’s revenue per employee was $1,344,007, whereas its income per employee was $338,756. Gross Margin for this corporation currently stands at +98.66% with Operating Margin at +28.03%, Pretax Margin comes in at +28.91%, and Net Margin reading is +25.20%. To continue investigating profitability, this company’s Return on Assets is posted at 20.11, Equity is 23.08, Total Capital is 25.62, and Invested Capital is 23.08. An extended look at the Principal structure reveals enduring liabilities to the total capital of 0.23 and enduring liabilities to assets of 0.20.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.11 points at the first support level, and at 23.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.81, and for the 2nd resistance point, it is at 25.09.

Corcept Therapeutics Incorporated [CORT] reported earnings per share of $0.14 for its fiscal quarter that ended on 3/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.19/share, meaning a difference of -$0.05 and a surprise factor of -26.30%. By comparison, the stated earnings for the previous quarter ended on 12/30/2022 were $0.14 per share as compared to estimates of $0.22 per share, a difference of -$0.08 representing a surprise of -36.40%.

Ratios To Look Out For

It’s worth pointing out that Corcept Therapeutics Incorporated [NASDAQ:CORT]’s Current Ratio is 6.80. Further, the Quick Ratio stands at 6.80, while the Cash Ratio is 5.95. Considering the valuation of this stock, the price to sales ratio is 5.86, the price to book ratio is 4.36 and the P/E (TTM) ratio is 30.12.

Transactions by insiders

Insider trading, which has resulted in 10 insider purchases of 13,894 shares and 0 insider sales of 0 shares in the past three months, is now the topic of our analysis. Recent insider trading involved Robb Gary Charles, Chief Business Officer, that happened on May 10 when 14000.0 shares were sold. Chief Business Officer, Robb Gary Charles completed a deal on May 09 to sell 30000.0 shares. Meanwhile, Maduck Sean sold 625.0 shares on Dec 01.